EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)

Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen‐reduced red cells in complex cardiac surgery patients

Philip J Norris iD, Mars Stone, Clara Di Germanio iD, Brendan Balasko, Zhanna Kaidarova, Henry Friend, Jeanne Varrone, Laurence Corash iD, Nina Mufti, Richard J Benjamin iD

Transfusion · 2025

DOI: 10.1111/trf.18131 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Transfusion, 2025. Verfasst von Philip J Norris und 9 weiteren Autor:innen. Beteiligte Einrichtung: Vitalant Research Institute, San Francisco, California, USA. Hauptthemen laut MEDLINE: Erythrocyte Transfusion, Isoantibodies, Glutathione, HLA Antigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Biomedical Advanced Research and Development Authority, US Dept of Health and Human Services, ClinicalTrials.gov.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although alloimmunization risk of pathogen‐reduced (PR) platelets has been studied, the risk has not been reported with PR red blood cells (RBCs). Study Design and Methods In a Phase III, randomized, controlled trial (Red Cell Pathogen Inactivation), cardiac or thoracic‐aorta surgery patients were randomized to transfusion with amustaline/glutathione PR versus conventional RBCs. Pre‐transfusion and Day 28 samples were evaluated for Human leukocyte antigen (HLA) Class I and Class II antibodies at low, medium, and high cutoff values.

Results

The HLA alloimmunization analysis included 114 participants (53% female) in the PR and 113 (51% female) in the conventional RBC arms. In a modified intention‐to‐treat analysis, 13.7% ( N = 29) and 7.2% ( N = 15) developed new high‐level HLA Class I or Class II antibodies, respectively; however, there was no signal that PR‐RBCs affected the rate of HLA Class I (odds ratio (OR) 1.3 [95% confidence interval (CI) 0.62–2.9]) or Class II antibody formation (OR 0.99 [95% CI 0.35–2.8]). Female transfusion recipients had higher risk of developing new high‐level HLA Class I antibodies (OR 12.0 [95% CI 3.5–40.9]) and Class II antibodies (OR 5.0 [95% CI 1.4–17]). The mean number of RBC (5.5 vs. 3.6 units, p = 0.018) and platelet (1.8 vs. 1.1 units, p = 0.043) transfusions was higher in subjects with new high‐level HLA Class II antibodies.

Discussion

Receipt of amustaline/glutathione PR‐RBC units did not affect HLA alloimmunization risk. Female sex and number of RBC and platelet transfusions were risk factors for the development of new high‐level HLA Class I and Class II antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erythrocyte TransfusionIsoantibodiesGlutathioneHLA AntigensCardiac Surgical ProceduresErythrocytesHumansFemaleMaleMiddle AgedAgedAcridinesNitrogen Mustard Compounds

Stichwörter der Autor:innen

RBC transfusionblood component preparationsimmunology (other than RBC serology)

Substanzen

IsoantibodiesGlutathioneHLA Antigens(N,N-bis(2-chloroethyl))-2-aminoethyl-3-((acridin-9-yl)amino)propionateAcridinesNitrogen Mustard Compounds

Autor:innen und Institutionen

  • Vitalant Research Institute, San Francisco, California, USA.
  • Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Cerus Corporation, Concord, California, USA.

ORCID-Profile: Philip J Norris, Clara Di Germanio, Laurence Corash, Richard J Benjamin

Förderung

  • Biomedical Advanced Research and Development Authority
  • US Dept of Health and Human Services
  • ClinicalTrials.gov
  • Cerus Corporation

Zitieren

APA

Norris, P. J., Stone, M., Di Germanio, C., Balasko, B., Kaidarova, Z., Friend, H., Varrone, J., Corash, L., Mufti, N., & Benjamin, R. J. (2025). Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen‐reduced red cells in complex cardiac surgery patients. Transfusion. https://doi.org/10.1111/trf.18131

Vancouver

Norris PJ, Stone M, Di Germanio C, Balasko B, Kaidarova Z, Friend H, et al. Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen‐reduced red cells in complex cardiac surgery patients. Transfusion. 2025. doi:10.1111/trf.18131

BibTeX
@article{Norris2025,
  author = {Norris, Philip J and Stone, Mars and Di Germanio, Clara and Balasko, Brendan and Kaidarova, Zhanna and Friend, Henry and Varrone, Jeanne and Corash, Laurence and Mufti, Nina and Benjamin, Richard J},
  title = {Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen‐reduced red cells in complex cardiac surgery patients},
  journal = {Transfusion},
  year = {2025},
  doi = {10.1111/trf.18131}
}
Kostenlos starten →